NEW YORK--(BUSINESS WIRE)--Tema ETFs (“Tema”), the New York-based provider of innovative exchange traded funds (ETFs), today announced the launch of the Tema International Durable Quality ETF. ITOL ...
Kadimastem Ltd. and Itolerance Inc. have held a type B pre-IND meeting with the FDA regarding the development of ITOL-102, an investigational biologic for the treatment and potential cure of type 1 ...
Approval Follows Successful Pre-IND Meeting with the U.S. FDA on iTOL-102, a Potential Cure for Type 1 diabetes that would circumvent the need for life-long immunosuppression drugs ZURICH, July 17, ...
ZURICH, Oct. 29, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd (NLSP). (Nasdaq: NLSP) ("NLS" or the "Company"), a biopharmaceutical company focused on developing innovative therapies for central nervous ...
The ITOL ETF is currently trading at $25.34, which represents a -0.39% change. Over the past 52 weeks, the ETF has traded as high as $25.44 and as low as $25.44. The expense ratio of ITOL is 0.6%.
NLS Pharmaceutics Ltd. (Nasdaq: NLSP”) (“NLS”) and Kadimastem Ltd. (“Kadimastem”), a clinical-stage company specializing in "off-the-shelf" allogeneic cell therapy products for neurodegenerative ...
There is no recent news for this security. Got a confidential news tip? We want to hear from you. Sign up for free newsletters and get more CNBC delivered to your inbox Get this delivered to your ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results